Davenport & CO LLC Durect Corp Transaction History

Davenport & CO LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$0.9 - $1.31 $185,760 - $270,384	-206,400 Reduced 55.31%	166,750 $164,000
Q2 2021 Jul 28, 2021	BUY	$1.6 - $2.02 $2,800 - $3,535	1,750 Added 0.47%	373,150 $608,000
Q4 2020 Jan 13, 2021	BUY	$1.65 - $2.43 $49,500 - $72,900	30,000 Added 8.79%	371,400 $769,000
Q3 2020 Oct 15, 2020	BUY	$1.6 - $2.35 $22,400 - $32,900	14,000 Added 4.28%	341,400 $584,000
Q2 2020 Jul 28, 2020	BUY	$1.33 - $2.76 $35,910 - $74,520	27,000 Added 8.99%	327,400 $760,000
Q1 2020 May 05, 2020	SELL	$0.97 - $2.85 $1.31 Million - $3.84 Million	-1,347,660 Reduced 81.77%	300,400 $466,000
Q4 2019 Jan 22, 2020	BUY	$1.69 - $3.8 $1.79 Million - $4.01 Million	1,056,540 Added 178.61%	1,648,060 $6.26 Million
Q2 2019 Jul 10, 2019	BUY	$0.51 - $0.86 $215,587 - $363,539	422,720 Added 250.43%	591,520 $386,000
Q1 2019 Apr 17, 2019	BUY	$0.51 - $0.82 $10,200 - $16,400	20,000 Added 13.44%	168,800 $106,000
Q4 2018 Jan 28, 2019	SELL	$0.48 - $1.1 $88,896 - $203,720	-185,200 Reduced 55.45%	148,800 $72,000
Q3 2018 Oct 11, 2018	SELL	$1.06 - $1.69 $29,468 - $46,982	-27,800 Reduced 7.68%	334,000 $367,000
Q2 2018 Jul 09, 2018	BUY	$1.56 - $2.51 $30,888 - $49,697	19,800 Added 5.79%	361,800 $564,000
Q1 2018 Apr 04, 2018	BUY	$0.91 - $2.24 $36,400 - $89,600	40,000 Added 13.25%	342,000 $732 Million
Q4 2017 Jan 17, 2018	BUY	$0.78 - $2.1 $106,860 - $287,700	137,000 Added 83.03%	302,000 $278 Million
Q3 2017 Oct 12, 2017	BUY	$1.55 - $1.82 $255,750 - $300,300	165,000	165,000 $292 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $230M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Davenport & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Davenport & CO LLC with notifications on news.